Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II TrialJianming Xu, Quanren Wang, Jie Shen et al.|Clinical Cancer Research|2020Cited by 576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III TrialShukui Qin, Feng Chen, Chengxu Cui et al.|Journal of Clinical Oncology|2021Cited by 417
Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: A multicenter study from ChinaQifan Zhan, Xiao Xu, Sunbin Ling et al.|Hepatobiliary & pancreatic diseases international|2020Cited by 26
Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).Yun Zhang, Quanren Wang, Jianming Xu et al.|Journal of Clinical Oncology|2021Cited by 10
983P Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trialJ. Xu, Qi Wang, Jie Shen et al.|Annals of Oncology|2020Cited by 5